Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications
{{output}}
Histone deacetylases (HDACs) have become an important target for the treatment of cancer and other diseases. Currently, more than ten HDAC inhibitors have entered clinical studies and two of them have already reached the market. The hydroxamic acid derivative ... ...
